Advertisement

Archives of Virology

, Volume 163, Issue 5, pp 1279–1284 | Cite as

Immunoregulation of Theiler’s virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses

  • Seiichi Omura
  • Fumitaka Sato
  • Nicholas E. Martinez
  • Tierra Range
  • Lesya Ekshyyan
  • Alireza Minagar
  • J. Steven Alexander
  • Ikuo Tsunoda
Brief Report

Abstract

While most disease-modifying drugs (DMDs) regulate multiple sclerosis (MS) by suppressing inflammation, they can potentially suppress antiviral immunity, causing progressive multifocal leukoencephalopathy (PML). The DMD glatiramer acetate (GA) has been used for MS patients who are at high risk of PML. We investigated whether GA is safe for use in viral infections by using a model of MS induced by infection with Theiler’s murine encephalomyelitis virus (TMEV). Treatment of TMEV-infected mice with GA neither enhanced viral loads nor suppressed antiviral immune responses, while it resulted in an increase in the Foxp3/Il17a ratio and IL-4/IL-10 production. This is the first study to suggest that GA could be safe for MS patients with a proven viral infection.

Notes

Acknowledgements

We thank Dr. Viromi Fernando and Dr. Eiichiro Kawai for their helpful discussions, and Ms. Sadie Faith Pearson and Ms. Elaine Cliburn Stewart for their excellent technical assistance.

Funding

This work was funded by the Teva Neuroscience Investigator-Initiated Program (TNSCOP0049), IDeA from the National Institute of General Medical Science of the NIH (5P30GM110703), KAKENHI from the Japan Society for the Promotion of Science (JP17K15628 and JP16H07356), Science Research Promotion Fund from the Promotion and Mutual Aid Corporation for Private Schools of Japan, and Kindai University Research Enhancement Grant.

Compliance with ethical standards

Conflict of interest

The decision to publish this article was solely the responsibility of the authors. All statements, opinions, and content presented in this article are those of the authors and do not represent the opinions of Teva. Teva provided a medical accuracy review of the article.

Ethical approval

All experimental procedures involving the use of animals were conducted according to the criteria outlined by the NIH and were approved by the IACUC of Louisiana State University.

Supplementary material

705_2018_3729_MOESM1_ESM.doc (2 mb)
Supplementary material 1 (DOC 2044 kb)

References

  1. 1.
    Johnson RT (1998) Chronic inflammatory and demyelinating diseases. In: Johnson RT (ed) Viral infections of the nervous system, 2nd edn. Lippincott-Raven, Philadelphia, pp 227–263Google Scholar
  2. 2.
    Wu GF, Dandekar AA, Pewe L, Perlman S (2000) CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. J Immunol 165:2278–2286CrossRefPubMedGoogle Scholar
  3. 3.
    Tsunoda I, Kurtz CIB, Fujinami RS (1997) Apoptosis in acute and chronic central nervous system disease induced by Theiler’s murine encephalomyelitis virus. Virology 228:388–393CrossRefPubMedGoogle Scholar
  4. 4.
    Sato F, Omura S, Kawai E, Martinez NE, Acharya MM, Reddy PC, Chaitanya GV, Alexander JS, Tsunoda I (2014) Distinct kinetics of viral replication, T cell infiltration, and fibrosis in three phases of myocarditis following Theiler’s virus infection. Cell Immunol 292:85–93CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Asakura K, Murayama H, Himeda T, Ohara Y (2002) Epitope-tagged L* protein of Theiler’s murine encephalomyelitis virus is expressed in the central nervous system in the acute phase of infection. J Virol 76:13049–13054CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Tsunoda I, Fujinami RS (2002) Inside-out versus outside-in models for virus induced demyelination: axonal damage triggering demyelination. Springer Semin Immunopathol 24:105–125CrossRefPubMedGoogle Scholar
  7. 7.
    Murray PD, Pavelko KD, Leibowitz J, Lin X, Rodriguez M (1998) CD4+ and CD8+ T cells make discrete contributions to demyelination and neurologic disease in a viral model of multiple sclerosis. J Virol 72:7320–7329PubMedPubMedCentralGoogle Scholar
  8. 8.
    Lipton HL, Twaddle G, Jelachich ML (1995) The predominant virus antigen burden is present in macrophages in Theiler’s murine encephalomyelitis virus-induced demyelinating disease. J Virol 69:2525–2533PubMedPubMedCentralGoogle Scholar
  9. 9.
    Ransohoff RM, Hafler DA, Lucchinetti CF (2015) Multiple sclerosis—a quiet revolution. Nat Rev Neurol 11:134–142CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802–812CrossRefPubMedGoogle Scholar
  11. 11.
    Ure DR, Rodriguez M (2002) Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J 16:1260–1262CrossRefPubMedGoogle Scholar
  12. 12.
    Sato F, Martinez NE, Shahid M, Rose JW, Carlson NG, Tsunoda I (2013) Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis. Am J Pathol 183:1390–1396CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Aharoni R, Sasson E, Blumenfeld-Katzir T, Eilam R, Sela M, Assaf Y, Arnon R (2013) Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate. Exp Neurol 240:130–144CrossRefPubMedGoogle Scholar
  14. 14.
    Aharoni R (2014) Immunomodulation neuroprotection and remyelination—the fundamental therapeutic effects of glatiramer acetate: a critical review. J Autoimmun 54:81–92CrossRefPubMedGoogle Scholar
  15. 15.
    Aharoni R, Eilam R, Stock A, Vainshtein A, Shezen E, Gal H, Friedman N, Arnon R (2010) Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J Neuroimmunol 225:100–111CrossRefPubMedGoogle Scholar
  16. 16.
    Martinez NE, Karlsson F, Sato F, Kawai E, Omura S, Minagar A, Grisham MB, Tsunoda I (2014) Protective and detrimental roles for regulatory T cells in a viral model for multiple sclerosis. Brain Pathol 24:436–451CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tsunoda I, Tanaka T, Saijoh Y, Fujinami RS (2007) Targeting inflammatory demyelinating lesions to sites of Wallerian degeneration. Am J Pathol 171:1563–1575CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven-Kreitman R, Tarcik N, Teitelbaum D (2001) Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®. J Neuroimmunol 115:152–160CrossRefPubMedGoogle Scholar
  19. 19.
    Arnon R, Aharoni R (2009) Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. J Neural Transm 116:1443–1449CrossRefPubMedGoogle Scholar
  20. 20.
    Zelinskyy G, Dietze K, Sparwasser T, Dittmer U (2009) Regulatory T cells suppress antiviral immune responses and increase viral loads during acute infection with a lymphotropic retrovirus. PLoS Pathog 5:e1000406CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Microbiology and ImmunologyLouisiana State University Health Sciences Center-ShreveportShreveportUSA
  2. 2.Center for Molecular and Tumor Virology, Louisiana State University Health Sciences Center-ShreveportShreveportUSA
  3. 3.Department of NeurologyLouisiana State University Health Sciences Center-ShreveportShreveportUSA
  4. 4.Department of Molecular and Cellular PhysiologyLouisiana State University Health Sciences Center-ShreveportShreveportUSA
  5. 5.Department of MicrobiologyKindai University Faculty of MedicineOsakasayamaJapan

Personalised recommendations